John J. Alam, chief executive officer and president of CervoMed Inc. (NASDAQ:CRVO), who also serves as a director and a 10% owner, acquired company shares valued at $152,621 on November 18, 2026. The purchases were executed through open-market transactions, with prices ranging from $1.514 to $1.53 per share. Alam bought 23,681 shares at $1.514 and an additional 76,319 shares at $1.53, for a total of 100,000 shares.
The stock currently trades at $1.33, down 21% over the past week, and is now trading near its 52-week low of $1.27. According to InvestingPro analysis, the stock appears undervalued at current levels, with the platform’s Fair Value estimate suggesting potential upside. InvestingPro offers 15 additional tips for CRVO, providing deeper insights into the company’s financial health and market position.
Following these transactions, Alam beneficially owns 1,584,078 shares of CervoMed common stock. This total includes 1,471,578 shares held jointly with his spouse, Dr. Sylvie Gregoire, PharmD., who is also a member of CervoMed’s Board of Directors. Additionally, 112,500 shares are held in the John J. Alam Roth IRA, and 12,500 shares are held indirectly through the Sylvie Gregoire Roth IRA.
In other recent developments, CervoMed presented initial data from its Phase 2a trial of neflamapimod, showing a reduction in mean plasma levels of neurofilament light chain over the first 12 weeks of treatment. The data was shared at the 15th International Society of Frontotemporal Dementias Annual Meeting in Philadelphia. H.C. Wainwright has reiterated a Buy rating on CervoMed stock with a $25.00 price target, highlighting the importance of these clinical trial results.
Additionally, CervoMed announced advancements in its drug development program, including a new 50mg oral tablet formulation of neflamapimod. These advancements allow for a higher-dose, twice-daily regimen, supported by the FDA’s removal of a previous plasma drug exposure limit. The controlled manufacturing process implemented by CervoMed is designed to ensure reproducible, large-scale tablet production. H.C. Wainwright also maintained its Buy rating following these announcements, indicating confidence in the company’s progress.